Bavarian Nordic bets on Adaptvac VLP technology for COVID-19 vaccine push May 6, 2020 By Cormac Sheridan No Comments DUBLIN – Bavarian Nordic A/S, Europe’s largest independent vaccine developer, is placing a bet on virus-like particle (VLP) technology as a potentially useful contribution to the desperate global effort to push back against SARS-CoV-2.Read More